Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
Aminohippurate Sodium is a diagnostic agent administered by injection used primarily for renal function assessment and effective renal plasma flow measurement. This legacy injectable was approved in 1944 and remains a specialized diagnostic tool in nephrology and urology settings. The drug facilitates visualization and quantification of kidney filtration capacity through its selective renal clearance.
This legacy diagnostic product faces declining volumes as newer imaging modalities replace traditional renal clearance testing, indicating small and specialized commercial teams.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on Aminohippurate Sodium offers minimal career growth opportunities given zero linked job openings and declining market relevance driven by technological obsolescence. This role suits professionals seeking stability in a niche legacy product or those transitioning to newer diagnostic innovations.
Worked on AMINOHIPPURATE SODIUM at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.